WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510287
CAS#: 72795-01-8 (HCl)
Description: ICI-118551, also known as ICI-118,551, is a selective beta-2 (β2) adrenergic receptor antagonist. ICI-118551 binds to the β2 subtype with at least 100 times greater affinity than β1 or β3, the two other known subtypes of the beta adrenoceptor. The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008. ICI-118,551 has no known therapeutic use in humans although it has been used widely in research to understand the action of the β2 adrenergic receptor, as few other specific antagonists for this receptor are known.
MedKoo Cat#: 510287
Name: ICI-118551 HCl
CAS#: 72795-01-8 (HCl)
Chemical Formula: C17H28ClNO2
Molecular Weight: 313.87
Elemental Analysis: C, 65.06; H, 8.99; Cl, 11.29; N, 4.46; O, 10.19
ICI-118551 HCl is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, SDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: ICI118551; ICI 118551; ICI-118551; ICI118,551; ICI 118,551; ICI-118,551; ICI-118551 HCl.
IUPAC/Chemical Name: (2R,3R)-3-(isopropylamino)-1-((7-methyl-2,3-dihydro-1H-inden-4-yl)oxy)butan-2-ol hydrochloride
InChi Key: KBXMBGWSOLBOQM-CACIRBSMSA-N
InChi Code: InChI=1S/C17H27NO2.ClH/c1-11(2)18-13(4)16(19)10-20-17-9-8-12(3)14-6-5-7-15(14)17;/h8-9,11,13,16,18-19H,5-7,10H2,1-4H3;1H/t13-,16+;/m1./s1
SMILES Code: C[C@@H](NC(C)C)[C@@H](O)COC1=CC=C(C)C2=C1CCC2.[H]Cl
The following data is based on the product molecular weight 313.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Moresco RM, Matarrese M, Soloviev D, Simonelli P, Rigamonti M, Gobbo C, Todde S, Carpinelli A, Kienle MG, Fazio F. Synthesis and in vivo evaluation of [11C]ICI 118551 as a putative subtype selective beta2-adrenergic radioligand. Int J Pharm. 2000 Aug 25;204(1-2):101-9. PubMed PMID: 11011992.
2: Hopkinson HE, Latif ML, Hill SJ. Non-competitive antagonism of beta(2)-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active beta(2)-adrenoceptors. Br J Pharmacol. 2000 Sep;131(1):124-30. PubMed PMID: 10960078; PubMed Central PMCID: PMC1572294.
3: Quaglia MG, Farina A, Bossu E. Analysis of ICI 118551, a new beta 2 blocking drug, and related compounds by RP-HPLC-DAD. J Pharm Biomed Anal. 1992 Oct-Dec;10(10-12):1081-4. PubMed PMID: 1363686.
4: Jefferson D, Wharrad HJ, Birmingham AT, Patrick JM. The comparative effects of ICI 118551 and propranolol on essential tremor. Br J Clin Pharmacol. 1987 Dec;24(6):729-34. PubMed PMID: 2894217; PubMed Central PMCID: PMC1386396.
5: King DJ, Devaney NM, Gilbert JK. A double-blind placebo controlled trial of a selective beta 2 adrenoceptor antagonist (ICI 118551) in chronic anxiety. Int Clin Psychopharmacol. 1987 Jul;2(3):191-200. PubMed PMID: 3320184.
6: Tattersfield AE, Cragg DJ. Effect of ICI 118551 on bronchial beta-adrenoceptor function and exercise heart rate in normal man. Br J Clin Pharmacol. 1983 Dec;16(6):587-90. PubMed PMID: 6140938; PubMed Central PMCID: PMC1428330.